Determination of the Optimal Time Interval for Repeat Evaluation After a Benign Thyroid Nodule Aspiration

Nou, Eric; Kwong, Norra; Alexander, Lukas K.; Cibas, Edmund S.; Marqusee, Ellen; Alexander, Erik K.

doi:10.1210/jc.2013-3160

Cited by 98 publications

(56 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At our institution the malignancy rate among nodules with documented growth is quite low (i.e. 1-2%), in agreement with other papers reporting thyroid lesions followed-up after an initial benign assessment [21][22][23][24]. Finally, in our series PTC/ FTC ratio was 72:1 (216/3 cases).…”

Section: Discussionsupporting

confidence: 91%

Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer

et al. 2016

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer

et al. 2016

View full text Add to dashboard Cite

“…The question is even how long should the follow-up be. According to Nou et al [53], who followed up 2,010 benign nodules for an average of 8.5 years (range 0.25–18), repeated thyroid nodule evaluation should be done 2–4 years after the initial benign FNA. 18 false-negative thyroid malignancies were diagnosed at a mean 4.5 years (range 0.3–10) after the initial benign biopsy.…”

Section: What Is the Evidence That Molecular Fna Diagnostics With A Gmentioning

confidence: 99%

“…However, a longer follow-up of 8.1 years was proposed by Liel et al [55]. Based on the data of Nou et al [53] a 2-year follow-up should be sufficient.…”

Section: What Is the Evidence That Molecular Fna Diagnostics With A Gmentioning

confidence: 99%

European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics

Paschke¹,

Cantara²,

Crescenzi³

et al. 2017

Eur Thyroid J

135

136

View full text Add to dashboard Cite

Molecular fine-needle aspiration (FNA) cytology diagnostics has the potential to address the inherent limitation of FNA cytology which is an indeterminate (atypia of undetermined significance/follicular lesion of undetermined significance follicular neoplasm) cytology. Because of the emerging role of molecular FNA cytology diagnostics, the European Thyroid Association convened a panel of international experts to review methodological aspects, indications, results, and limitations of molecular FNA cytology diagnostics. The panel reviewed the evidence for the diagnostic value of mutation panel assessment (including at least BRAF, NRAS, HRAS, KRAS, PAX8/PPARG, RET/PTC) of targeted next generation sequencing and of a microarray gene expression classifier (GEC) test in the diagnostic assessment of an indeterminate cytology thyroid nodule. Moreover, possible surgical consequences of molecular FNA diagnostic results of thyroid nodules and the evidence that analysis of a molecular FNA diagnostic panel of somatic mutations or a microarray GEC test can alter the follow-up were reviewed. Molecular tests may help clinicians to drive patient care and the surgical decision if the analysis is performed in specialized laboratories. These molecular tests require standardization of performance characteristics and appropriate calibration as well as analytic validation before clinical interpretation.

show abstract

“…Several recent studies have confirmed that the ROM is very low for this category [4,21,22]. Risk stratification based upon ultrasound patterns (ATA 2015 revised guidelines) can be used to guide clinical follow-up of thyroid nodules with benign cytology [4].…”

Section: Specific Issues Pertaining To the Different Diagnostic Categmentioning

confidence: 99%

The Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel

Pusztaszeri

Rossi

Auger³

et al. 2016

Acta Cytologica

114

View full text Add to dashboard Cite

The Bethesda System for Reporting Thyroid Cytology (TBSRTC) was proposed in 2007 at the National Cancer Institute Thyroid Fine Needle Aspiration State of the Art and Science Conference held in Bethesda, Maryland. The aim was to address the inconsistent and sometimes confusing reporting terminologies used for thyroid FNA throughout the world. The TBSRTC consists of 6 diagnostic categories, each associated with an implied risk of malignancy that translates directly into a clinical management algorithm. Since the publication of the TBSRTC cytology Atlas in January 2010, considerable experience has been gained regarding its application in cytology practice, clinical impact, and limitations. In conjunction with the International Academy of Cytology (IAC), an international panel composed of sixteen cytopathologists and an endocrinologist with special interest in thyroid cytology, including several co-authors of the 2010 TBSRTC Atlas, was created to: (1) analyze the current worldwide impact of TBSRTC, (2) report on the current state of TBSRTC based upon a review of the published literature, and (3) provide possible recommendations for a future update of TBSRTC. Herein, we summarize the panel's deliberations and key recommendations that our panel hopes will be useful during the preparation of the second edition of TBSRTC.

show abstract

Determination of the Optimal Time Interval for Repeat Evaluation After a Benign Thyroid Nodule Aspiration

Cited by 98 publications

References 17 publications

Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer

Early diagnosis by FNA cytology should not influence the outcome of differentiated thyroid cancer

European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics

The Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel

Contact Info

Product

Resources

About